Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2021 Sep 9

PMID 34497848

Citations 8

Authors

Wote Amelo

Eyasu Makonnen

Affiliations

Soon will be listed here.

Abstract

Since 2000, a good deal of progress has been made in malaria control. However, there is still an unacceptably high burden of the disease and numerous challenges limiting advancement towards its elimination and ultimate eradication. Among the challenges is the antimalarial drug resistance, which has been documented for almost all antimalarial drugs in current use. As a result, the malaria research community is working on the modification of existing treatments as well as the discovery and development of new drugs to counter the resistance challenges. To this effect, many products are in the pipeline and expected to be marketed soon. In addition to drug and vaccine development, mass drug administration (MDA) is under scientific scrutiny as an important strategy for effective utilization of the developed products. This review discusses the challenges related to malaria elimination, ongoing approaches to tackle the impact of drug-resistant malaria, and upcoming antimalarial drugs.

Citing Articles

Exploring Genetic Silencing: RNAi and CRISPR-Cas Potential against Drug Resistance in Malaria.

Gaona-Lopez C, Rivera G Mini Rev Med Chem. 2024; 25(2):128-137.

PMID: 38932611 DOI: 10.2174/0113895575306957240610102626.

Leveraging computational tools to combat malaria: assessment and development of new therapeutics.

Ncube N, Tukulula M, Govender K J Cheminform. 2024; 16(1):50.

PMID: 38698437 PMC: 11064327. DOI: 10.1186/s13321-024-00842-z.

Current Status of Malaria Control and Elimination in Africa: Epidemiology, Diagnosis, Treatment, Progress and Challenges.

Li J, Docile H, Fisher D, Pronyuk K, Zhao L J Epidemiol Glob Health. 2024; 14(3):561-579.

PMID: 38656731 PMC: 11442732. DOI: 10.1007/s44197-024-00228-2.

Bioassay-Guided Isolation of Antiplasmodial Compounds from Lam. (Hypericaceae) and Their Cytotoxicity and Molecular Docking.

Happi G, Ahmed S, Kemayou G, Salau S, Dzouemo L, Sikam K Biomed Res Int. 2023; 2023:4693765.

PMID: 37284030 PMC: 10241580. DOI: 10.1155/2023/4693765.

Drug Development Strategies for Malaria: With the Hope for New Antimalarial Drug Discovery-An Update.

Pandey S, Anand U, Siddiqui W, Tripathi R Adv Med. 2023; 2023:5060665.

PMID: 36960081 PMC: 10030226. DOI: 10.1155/2023/5060665.

References

Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M . Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science. 1999; 285(5433):1573-6. DOI: 10.1126/science.285.5433.1573. View

Sisowath C, Petersen I, Veiga M, Martensson A, Premji Z, Bjorkman A . In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009; 199(5):750-7. PMC: 2718568. DOI: 10.1086/596738. View

Staines H, Burrow R, Teo B, Chis Ster I, Kremsner P, Krishna S . Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis. J Antimicrob Chemother. 2017; 73(3):581-595. PMC: 5890752. DOI: 10.1093/jac/dkx431. View

Magistrado P, Corey V, Lukens A, LaMonte G, Sasaki E, Meister S . Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes. ACS Infect Dis. 2016; 2(11):816-826. PMC: 5109296. DOI: 10.1021/acsinfecdis.6b00025. View

Llanos-Cuentas A, Casapia M, Chuquiyauri R, Hinojosa J, Kerr N, Rosario M . Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. Lancet Infect Dis. 2018; 18(8):874-883. PMC: 6060173. DOI: 10.1016/S1473-3099(18)30309-8. View

. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015; 386(9988):31-45. PMC: 5626001. DOI: 10.1016/S0140-6736(15)60721-8. View

Brady O, Slater H, Pemberton-Ross P, Wenger E, Maude R, Ghani A . Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. Lancet Glob Health. 2017; 5(7):e680-e687. PMC: 5469936. DOI: 10.1016/S2214-109X(17)30220-6. View

Paquet T, Le Manach C, Gonzalez Cabrera D, Younis Y, Henrich P, Abraham T . Antimalarial efficacy of MMV390048, an inhibitor of phosphatidylinositol 4-kinase. Sci Transl Med. 2017; 9(387). PMC: 5731459. DOI: 10.1126/scitranslmed.aad9735. View

Peterson D, Milhous W, Wellems T . Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci U S A. 1990; 87(8):3018-22. PMC: 53825. DOI: 10.1073/pnas.87.8.3018. View

10.

Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H . Emergence of Indigenous Artemisinin-Resistant Plasmodium falciparum in Africa. N Engl J Med. 2017; 376(10):991-3. DOI: 10.1056/NEJMc1612765. View

11.

Leong F, Zhao R, Zeng S, Magnusson B, Diagana T, Pertel P . A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother. 2014; 58(11):6437-43. PMC: 4249437. DOI: 10.1128/AAC.03478-14. View

12.

Burrows J, Burlot E, Campo B, Cherbuin S, Jeanneret S, Leroy D . Antimalarial drug discovery - the path towards eradication. Parasitology. 2013; 141(1):128-39. PMC: 3884835. DOI: 10.1017/S0031182013000826. View

13.

Baragana B, Hallyburton I, Lee M, Norcross N, Grimaldi R, Otto T . A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015; 522(7556):315-20. PMC: 4700930. DOI: 10.1038/nature14451. View

14.

Flannery E, Chatterjee A, Winzeler E . Antimalarial drug discovery - approaches and progress towards new medicines. Nat Rev Microbiol. 2013; 11(12):849-62. PMC: 3941073. DOI: 10.1038/nrmicro3138. View

15.

Kimani J, Phiri K, Kamiza S, Duparc S, Ayoub A, Rojo R . Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial. PLoS One. 2016; 11(6):e0157045. PMC: 4915657. DOI: 10.1371/journal.pone.0157045. View

16.

Ashley E, Phyo A . Drugs in Development for Malaria. Drugs. 2018; 78(9):861-879. PMC: 6013505. DOI: 10.1007/s40265-018-0911-9. View

17.

Fidock D, Rosenthal P, Croft S, Brun R, Nwaka S . Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov. 2004; 3(6):509-20. DOI: 10.1038/nrd1416. View

18.

Coelho C, Doritchamou J, Zaidi I, Duffy P . Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium. NPJ Vaccines. 2018; 2:34. PMC: 5709382. DOI: 10.1038/s41541-017-0035-3. View

19.

Gatton M, Chitnis N, Churcher T, Donnelly M, Ghani A, Godfray H . The importance of mosquito behavioural adaptations to malaria control in Africa. Evolution. 2013; 67(4):1218-30. PMC: 3655544. DOI: 10.1111/evo.12063. View

20.

Koita O, Sangare L, Miller H, Sissako A, Coulibaly M, Thompson T . AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. Lancet Infect Dis. 2017; 17(12):1266-1275. PMC: 5700806. DOI: 10.1016/S1473-3099(17)30365-1. View